Researchers have announced a major breakthrough in cancer immunotherapy that could significantly improve survival rates for patients with aggressive tumors.
The new treatment approach uses modified T-cells to target and destroy cancer cells more effectively than existing therapies.
Research Findings
- 90% response rate in trials
- Fewer side effects than chemo
- Works on multiple cancer types
- FDA fast-track approval expected
Clinical trials are expanding to include more patients, with hopes for regulatory approval within two years.
Share this news
